Skip to main content
Premium Trial:

Request an Annual Quote

Newfound Genomics Inks Dx Deals with Genesis Group, PGxHealth

NEW YORK (GenomeWeb News) – Newfound Genomics, a genetic research and genotyping services firm based in St. Johns, Newfoundland, today said that it has signed a memorandum of understanding with the Genesis Group that provides Newfound with the opportunity to commercialize certain discoveries from Memorial University in the field of human genetics.
Genesis Group is the commercialization arm of the university, where Newfound CEO Wayne Gulliver is a professor of medicine and dermatology. The tech transfer group also inked a second pact with Newfound that provides the firm with certain exclusive rights to develop and market a test for arrhythmogenic right ventricular cardiomyopathy.
Concurrent with that pact, Newfound granted an exclusive sub-license to Clinical Data’s PGxHealth unit to perform and market a test to diagnose AVRC in the US, Europe, and certain other undisclosed territories.
Gulliver said that Newfound “will be making this test available in a matter of weeks.”

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.